This week, manufacturers of vaccine against influenza will make every effort to ensure that immunization is the widest. Update on vaccine not always very effective, but can save lives.
The Group Study and Information on Influenza (Geiger), an association law 1901 which comprises five manufacturers and distributors of vaccines on the French market (Sanofi Pasteur MSD, Chiron Vaccines France, GlaxoSmithKline, Pierre Fabre Medicament and Solvay Pharma) launches this week in a pharmacy a poster campaign to encourage people who have not yet done so to get vaccinated. So far the flu has not shown the tip of her nose cold.
Seasonal flu affects 2 to 7 million people in France each winter, resulting in 1 500 to 2 000 deaths annually in the elderly or subjects of any age weakened by a chronic disease (cardiac, pulmonary, metabolic, immunological, cancerous) . The flu can also cause complications.
Vaccination is usually held in October and November, but the labs say in their campaign, "there is still time to get vaccinated, knowing that the protection against influenza is effective ten to fifteen days later. "
In fact, vaccination does not protect a systematic and complete. In studies published to date vaccination to age, nutritional status and the type of virus protection against the disease that ranges from 0 to 60%. However, in people at risk can reduce mortality (up to 50-60% in some studies). The risk of complications and hospitalization is decreased in more modest, ranging from 20 to 30%.
Children and adults with asthma, and people with chronic pulmonary obstructive disease (COPD), even if they are under 65, people are susceptible to influenza. An estimated 3.1 million the number of people under 65 years with asthma. The flu causes a deterioration of ventilatory function, both in children than in adults.
The chronic pulmonary obstructive, or COPD, affects France 575 000 people under 65. It is manifested by chronic bronchitis (chronic cough with production of secretions) and difficulty breathing. Flu increases the cough and worsening shortness of breath which can lead to acute respiratory failure.
This year, the National Health Insurance has expanded the management of influenza vaccines for children and adults with asthma (all types) and people with COPD.
There are cons-indications to the vaccine: allergies to egg protein, history of vaccine reactions, Guillain-Barre syndrome after vaccination. The feverish and unwell people should wait to be restored before being vaccinated.
Some vaccines contain thimerosal, an ethylmercury compound salt and thiosalicylate, which acts as a preservative and sterilization. Thiomersal may take several designations: thimerosal, merthiolate, sodium ethylmercurethiosalicylate timerfonate or sodium. According to a report by the French Agency for the Safety of Health Products of 2003 "the amount of thimerosal contained in Fluarix (traces), Fluvirin (trace) and Influvac" is not considered at risk among target groups usual. Nevertheless, thimerosal can cause local reactions and LaNutrition wants everything to be done to remove any salt of mercury vaccines.
The Group Study and Information on Influenza (Geiger), an association law 1901 which comprises five manufacturers and distributors of vaccines on the French market (Sanofi Pasteur MSD, Chiron Vaccines France, GlaxoSmithKline, Pierre Fabre Medicament and Solvay Pharma) launches this week in a pharmacy a poster campaign to encourage people who have not yet done so to get vaccinated. So far the flu has not shown the tip of her nose cold.
Seasonal flu affects 2 to 7 million people in France each winter, resulting in 1 500 to 2 000 deaths annually in the elderly or subjects of any age weakened by a chronic disease (cardiac, pulmonary, metabolic, immunological, cancerous) . The flu can also cause complications.
Vaccination is usually held in October and November, but the labs say in their campaign, "there is still time to get vaccinated, knowing that the protection against influenza is effective ten to fifteen days later. "
In fact, vaccination does not protect a systematic and complete. In studies published to date vaccination to age, nutritional status and the type of virus protection against the disease that ranges from 0 to 60%. However, in people at risk can reduce mortality (up to 50-60% in some studies). The risk of complications and hospitalization is decreased in more modest, ranging from 20 to 30%.
Children and adults with asthma, and people with chronic pulmonary obstructive disease (COPD), even if they are under 65, people are susceptible to influenza. An estimated 3.1 million the number of people under 65 years with asthma. The flu causes a deterioration of ventilatory function, both in children than in adults.
The chronic pulmonary obstructive, or COPD, affects France 575 000 people under 65. It is manifested by chronic bronchitis (chronic cough with production of secretions) and difficulty breathing. Flu increases the cough and worsening shortness of breath which can lead to acute respiratory failure.
This year, the National Health Insurance has expanded the management of influenza vaccines for children and adults with asthma (all types) and people with COPD.
There are cons-indications to the vaccine: allergies to egg protein, history of vaccine reactions, Guillain-Barre syndrome after vaccination. The feverish and unwell people should wait to be restored before being vaccinated.
Some vaccines contain thimerosal, an ethylmercury compound salt and thiosalicylate, which acts as a preservative and sterilization. Thiomersal may take several designations: thimerosal, merthiolate, sodium ethylmercurethiosalicylate timerfonate or sodium. According to a report by the French Agency for the Safety of Health Products of 2003 "the amount of thimerosal contained in Fluarix (traces), Fluvirin (trace) and Influvac" is not considered at risk among target groups usual. Nevertheless, thimerosal can cause local reactions and LaNutrition wants everything to be done to remove any salt of mercury vaccines.
No comments:
Post a Comment